Orthofix Medical (OFIX) Stock Analysis & AI Equity Report
Orthofix Medical (OFIX) overview
Orthofix Medical (OFIX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 822m and operating profit of USD -81.4m; the year-end share price was 15.16 USD and market capitalisation was USD 604m. Orthofix Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Orthofix Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Orthofix Medical
Orthofix Medical develops and sells medical technologies for musculoskeletal conditions. Its products include spinal hardware and implants, biologics, bone growth therapies, limb reconstruction solutions, and enabling technologies such as the 7D FLASH Navigation System. Its Global Spine segment serves patients with spinal diseases and injuries through implantable devices and regenerative solutions.
Generate the Orthofix Medical report
Orthofix Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Orthofix Medical and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Orthofix Medical
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.